S.No | Treatment groups | Dose (mg/kg) | SGPT (IU) | SGOT (IU) | ALP (IU) | BUN (mg/dl) | Serum creatinine (mg/ml) |
---|---|---|---|---|---|---|---|
1 | aNormal control | 0.3 ml | 20 ± 5.6*** | 16 ± 3.5*** | 141 ± 7.2** | 18.5 ± 3.5** | 0.527 ± 0.2*** |
2 | bDiabetic control | 0.3 ml | 62.47 ± 7.5 | 62.27 ± 6.1 | 272.57 ± 8.3 | 35.7 ± 4.5 | 2.57 ± 0.2 |
3 | cGlibenclamide | 0.5 | 24.5 ± 6.4*** | 20.07 ± 3.6*** | 142.47 ± 9.3*** | 17.6 ± 2.3** | 0.56 ± 0.2*** |
4 | cMe-Ext | 100 | 44.56 ± 6.0* | 39.17 ± 3.9** | 197.39 ± 10.33* | 21.4 ± 5.4** | 1.50 ± 0.3* |
5 | cMe-Ext | 200 | 30.37 ± 8.0** | 21.97 ± 5.6*** | 160.19 ± 12.23** | 20.3 ± 3.2** | 0.85 ± 0.2** |
6 | cChf-Ext | 100 | 45.70 ± 4.5** | 34.37 ± 3.5** | 174.22 ± 8.5* | 24.6 ± 4.5* | 1.46 ± 0.2* |
7 | cChf-Ext | 200 | 28.80 ± 3.5* | 22.37 ± 4.5** | 154.32 ± 11.5** | 18.6 ± 2.5** | 0.76 ± 0.2** |
8 | cEtAC-Ext | 100 | 38.70 ± 4.5* | 45.37 ± 2.8* | 185.50 ± 17.2* | 25.5 ± 5.2* | 1.7 ± 0.3* |
9 | cEtAC-Ext | 200 | 28.85 ± 3.5** | 25.37 ± 3.5** | 165.50 ± 11.2** | 21.5 ± 6.2** | 1.2 ± 0.2* |